Table 1: Baseline characteristics of the control and trimetazidine groups.

CharacteristicsControl groupTrimetazidine group values

Cases (n)4948
Age (years)64.22 ± 10.5465.59 ± 12.070.399
Gender (male/female)31/1827/210.766
Hypertension (yes/no)30/1930/180.412
Diabetes (yes/no)11/388/400.195
Cerebral infarction (yes/no)4/458/400.240
Atrial fibrillation (yes/no)2/471/470.845
Smoking (yes/no)36/1331/170.353
TC (mmol/L)5.09 ± 1.084.86 ± 1.070.525
TG (mmol/L)2.26 ± 1.921.78 ± 1.010.208
LDL-C (mmol/L)2.94 ± 0.892.78 ± 0.640.627
HDL-C (mmol/L)1.21 ± 0.381.12 ± 0.230.294
LVEF0.56 ± 6.320.55 ± 7.830.822
Arterial stenosis (n)2.26 ± 0.812.46 ± 0.730.389
Stent (n)1.54 ± 0.741.68 ± 0.820.130
Blood collection time after PCI (h)16.70 ± 2.4616.68 ± 3.420.543

TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction.